Commentary|Articles|July 28, 2026

Beyond the trials: Pegcetacoplan slows GA progression in eyes with concurrent nAMD

Author(s)Hasenin Al-khersan MD, Martin David Harp, Kassi Filkins

Hasenin Al-khersan, MD, of the Retina Group of Florida, shares real-world RCA registry findings showing that pegcetacoplan significantly reduced both photoreceptor and RPE loss in eyes with GA.

Geographic atrophy (GA), secondary to age-related macular degeneration (AMD), remains one of the most challenging conditions in retina, and while pegcetacoplan (Syfovre) has established itself as a treatment option for GA, its pivotal trials excluded a substantial real-world population: patients with GA and concurrent neovascular AMD.